ANI Pharmaceuticals Q2 Earnings: What to Expect and How to Prepare

ANI Pharmaceuticals is set to report Q2 earnings on Friday. Analysts expect a 38.7% YoY revenue increase to $191.5 million and adjusted EPS of $1.42. The company has beaten revenue expectations in the last two years and has a strong track record of outperforming. The pharmaceuticals sector has underperformed in recent months, but ANI Pharmaceuticals is up 6.2% and has an average analyst price target of $81.38.

ANI Pharmaceuticals (NASDAQ: ANIP) is scheduled to release its second-quarter 2025 financial results on Friday, August 8, 2025, prior to the market open. Analysts are anticipating a robust performance, with revenue expected to grow by 38.7% year over year (YoY) to $191.5 million and adjusted earnings per share (EPS) of $1.42 [1].

The specialty pharmaceutical company has shown a strong track record of outperforming revenue expectations. In the previous quarter, ANI Pharmaceuticals beat analysts’ revenue expectations by 9.8%, reporting revenues of $197.1 million, up 43.4% YoY. The company also exceeded analysts’ EPS estimates and provided full-year revenue guidance that slightly topped expectations [1].

The pharmaceuticals sector has underperformed in recent months, with share prices down 5.7% on average over the last month. However, ANI Pharmaceuticals has bucked this trend, rising by 6.2% during the same period. The company is heading into earnings with an average analyst price target of $81.38, compared to its current share price of $69.09 [1].

Analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to continue on its current trajectory. ANI Pharmaceuticals has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 6.9% on average [1].

The company's peers in the pharmaceuticals segment have provided some insights into what to expect. Amneal delivered year-on-year revenue growth of 3.2%, missing analysts’ expectations by 2.5%, while Bristol-Myers Squibb reported flat revenue, topping estimates by 7.8% [1].

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in various therapeutic areas, its Generics business, and its Brands business [2].

Investors are encouraged to tune in to the conference call on Friday, August 8, 2025, at 8:30 a.m. ET, where Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, Chris Mutz, Head of Rare Disease, and Mary Pao, M.D., Ph.D., Chief Medical Officer, will discuss the results.

References:
[1] https://finance.yahoo.com/news/ani-pharmaceuticals-anip-q2-earnings-030137544.html
[2] https://www.biospace.com/press-releases/ani-pharmaceuticals-to-discuss-second-quarter-2025-financial-results-on-august-8-2025-at-8-30-a-m-et